Karabay EA, et al. - In this single-centre observational study involving 100 patients (39 female and 61 male) with chronic plaque-type psoriasis, researchers analyzed the impacts of systemic therapies on C-reactive protein (CRP) and the neutrophil-lymphocyte ratio (NLR) in psoriasis. For this investigation, they prospectively assessed psoriasis patients treated with narrow band ultraviolet B, acitretin, cyclosporine, methotrexate, adalimumab, etanercept, and ustekinumab. The data presented in this work showed a statistically significant reduction in PASI scores, CRP, and NLR values from the baseline to the 12-week visit. Positively correlated was the reduction of PASI scores and NLR values. Systemic psoriasis therapy has been demonstrated in the present study to decrease the levels of CRP and NLR, known as indicators of systemic inflammation and cardiovascular comorbidities.